Hanmi’s T2D drug curbs cardiovascular, kidney issues To view this email as a web page,
click here | By Amirah Al Idrus Chalk another one up for Eli Lilly’s next-generation diabetes drug. All three doses of tirzepatide beat placebo at lowering blood sugar and body weight in adults with early-stage Type 2 diabetes, more than half of whom had never tried a diabetes-specific treatment. read more |
| |
|---|
|
| By Fraiser Kansteiner Novo Nordisk has data showing 2-mg Ozempic topped its lower-dose predecessor on blood sugar and weight reduction. Side effects were on par with the lower dose, too, which could quiet analyst concerns about the potential popularity of stronger GLP-1 meds. read more |
| |
|---|
|
| By Eric Sagonowsky Years ago, Sanofi's Soliqua hit the diabetes market with the promise of combining an insulin and a GLP-1 medicine in a convenient once-daily treatment option. So far, though, sales haven't quite matched that promise. With new data, Sanofi is hoping to change that. read more |
| |
|---|
|
| By Amirah Al Idrus Hanmi Pharmaceuticals may no longer have a diabetes partner in Sanofi, but newly released results for its GLP-1 drug could move the needle for Type 2 diabetes patients with a history of cardiovascular disease, kidney disease or both. Efpeglenatide reduced their risk of heart attack, stroke and death and also slowed decline in patients’ kidney function, new data show. read more |
| |
|---|
|
| By Kevin Dunleavy At the American Diabetes Association’s Scientific Sessions, AstraZeneca presented positive results of a phase 3 trial of Bydureon, the first to be completed by a once-weekly GLP-1 receptor agonist on children and adolescents with type 2 diabetes. read more |
| |
|---|
|
| By Conor Hale Though the review of its 180-day implantable glucose sensor has faced FDA delays during the COVID-19 pandemic, Senseonics was able to deliver clinical data on its accuracy at two diabetes meetings this month. read more |
| |
|---|
|
| By Arlene Weintraub Researchers at Massachusetts General Hospital have spent the last two decades building up data to support their idea of repurposing the old tuberculosis vaccine BCG in type 1 diabetes. Now they have new data backing up their finding that the vaccine restores the ability of regulatory T cells (Tregs) to prevent the destruction of insulin-producing pancreatic islets. read more |
| |
|---|
|
| By Conor Hale For young children with Type 1 diabetes and their parents, Insulet hopes its newest artificial pancreas system can make the “terrible twos” a little more manageable for everyone. read more |
| |
|---|
|
| By Andrea Park Medtronic’s smart insulin pen doesn’t merely provide the convenience of a one-stop shop for diabetes management—according to newly released data, it’s also highly effective at regulating blood sugar levels and reducing instances of hypoglycemia. read more |
| |
|---|
|
|
|
